Govinda Bhisetti joined Cellarity in July 2022 as Vice President, Computational Chemistry. He has more than 30 years of industry experience in computational drug design. He was successful in designing and optimizing lead compounds against may targets to find drugs against viral infections, cancer, autoimmune, neuroinflammation and neurodegeneration diseases.
Prior to joining Cellarity, Govinda was Principal Investigator and the head of Computational Chemistry at Biogen. He built a strong computational chemistry group with advanced computational chemistry capabilities for In Silico drug design. He worked at Biogen for 8 years to advance several projects from exploratory stage to preclinical stage. He contributed to discovery of BIIB1113 (OGA inhibitor), currently in Phase 1 clinical trials. He established internal and external collaborations to enhance Biogen’s computational capabilities to expand the targets that can be modulated by small molecules. He worked on Post-Doctoral committee and helped recruit young scientists to Biogen. He mentored a post-doctoral fellow and several summer interns/coop students.
Prior to Biogen, Govinda worked at Vertex Pharmaceuticals for 22 years where he led drug design efforts on several drug discovery projects. His work at Vertex led to the discovery of three FDA approved drugs: Agenerase, Lexiva and Incivek, and several clinical candidates. He is a co-inventor of these drugs and named inventor on 26 patents.
Govinda got my Ph.D. from Indian Institute of Science, Bangalore, India and worked as a post-doctoral fellow at Scripps Research Institute, La Jolla, CA. His work at Scripps involved use of Cray XMP supercomputer to simulate protein-ligand interactions and design novel inhibitors. He carried out advanced Molecular Dynamics and Free Energy Perturbation simulations on aspartic proteases (rhizopus pepsin and HIV-1 proteae) and non-aqueous solvents. He published 75 research papers including review articles and book chapters.
Recent Comments